Norwegian Cartilage Project - Microfracture

Cartilage Injury Clinical Trial

Official title:

Focal Cartilage Defects in the Knee - A Randomized Controlled Trial Comparing Arthroscopic Microfracture With Arthroscopic Debridement

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02637505
• Other study ID #: 2015/2202
• Status: Completed
• Phase: N/A
• Start date: January 2016
• Est. completion date: September 28, 2022

Study information

• Verified date: August 2023
• Source: University Hospital, Akershus
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

114 patients between 18 and 50 years with an isolated focal cartilage defect in the knee will be randomized to either receive arthroscopic microfracture or arthroscopic debridement. Both groups will then undergo a systematic physiotherapy training regime for 6-9 months. The groups will then be compared for results, after 3, 6, 12 and 24 months, by using validated patient reported outcome scores (Lysholm, KOOS, Tegner) and EQ5D as well as clinical examination and radiological findings at 2 years (MRI).

Description:

Focal cartilage defects in the knee - A randomized controlled trial comparing arthroscopic microfracture with arthroscopic debridement. Clinical compare the effect of arthroscopic microfracture (MF) with arthroscopic debridement (AD) in patients with symptomatic full thickness knee cartilage injuries less than 2cm2. Focal cartilage injuries in the knee might have devastating effect both in the short term and in the long term. Various surgical treatment options are available, with microfracture the most used technique globally. Meta-analysis and systematic reviews have required well-designed, long-term, multicenter studies to evaluate clinical outcomes of microfracture with the use of a "no treatment" group as a control group. H0: There is no difference in KOOS QoL after AM or AD 24 months after surgery. H1: There is a difference in KOOS QoL after AM or AD 24 months after surgery. Questionnaires: KOOS, Tegner score, Lysholm score, EQ-5D, VAS. Physical examination: range of motion and hop test. Radiology: x-ray and MRI of the knee. Primary aim: KOOS quality of life (QoL) subscore. Prospective, double-blinded parallel-group multicenter study with 2 treatment arms. Approx. 24 months inclusion and 24 months follow up. In total 4 years. All will be invited to participate in late controls after 5 and 10 years. 6 Norwegian hospitals: Akershus University Hospital, Oslo University Hospital - Ullevaal, Kristiansund Hospital, Aalesund Hospital, Diakonhjemmet Hospital and Haukeland University Hospital. 114 patients Inclusion: age 18-50 years old, single symptomatic cartilage defect on femoral condyle or trochlea. 2 treatment groups with 57 patients in each group. Follow up after 3 months (± 2 weeks), 6 months (± 4 weeks), 12 months (± 6 weeks) and 24 months (± 8 weeks). All will be invited to participate in late controls after 5 and 10 years. If any unforeseen complication outside normal clinical practice occurs, the sponsor representative will be contacted as soon as possible with a parallel message to the local coordinators at the involved hospitals. During each follow up, there will be a case report form (CRF) regarding complications and safety. A 5 mL venous blood sample will be drawn on the day of operation. The blood sample will be centrifuged before serum is pipetted in a sterile tube. The serum will be analyzed at Oslo University Hospital - Rikshospitalet on the cartilage biomarker microRNA-140 (miR-140). If normal distribution, aims will be analyzed using linear mixed models (LMM), and the primary aim will be performed as a post hoc test for the LMM, similar to performing a two-sample t-test. If no normal distribution, analysis will be performed using Mann-Whitney U-test. Detecting a difference of 10 with 80 percent Power, uing a standard deviation of 18, this yields 52 patients in each group. By adding 10% due to loss during follow-up, we therefore plan to include a total of 114 patients. No interim analysis will be done. Monitor from Health Møre and Romsdal HF. The end of this study is 24 months after the last included patient.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 66
• Est. completion date: September 28, 2022
• Est. primary completion date: September 28, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Single symptomatic lesion of the trochlea, medial or lateral femoral condyle of the knee less than 2 cm2
• Cartilage lesion ICRS grade 3 or 4
• More than 50 % of the menisci intact
• Ligamentous stable knee
• Lysholm Score < 75
• Acceptable range of motion (5-105 degrees)

Exclusion Criteria:

• Osteoarthritis
• Malalignment > 5 degrees measured clinically, and if uncertainty on HKA radiographs
• Systemic arthritis
• Previous cartilage surgery except OCD fixation
• Obesity BMI > 30
• Serious drig or alcohol abuse
• Inability to answer questionnaires or partake in rehabilitation
• Comorbidity that may influence surgery or rehabilitation
• Pregnancy

Related Conditions & MeSH terms

• Cartilage Injury
• Fractures, Stress
• Knee Injuries
• Knee Injury
• Wounds and Injuries

Intervention

Procedure:
• Arthroscopic microfracture (MF)
Arthroscopy With microfracture procedure
• Arthroscopic debridement (AD)
Arthroscopy With debridement procedure

Locations

Country	Name	City	State
Norway	Akershus University Hospital	Lørenskog

Sponsors (7)

Lead Sponsor	Collaborator
University Hospital, Akershus	Alesund Hospital, Diakonhjemmet Hospital, Haraldsplass Deaconess Hospital, Haukeland University Hospital, Kristiansund Hospital, Oslo University Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Knee Injury and Osteoarthritis Outcome Score (KOOS) Quality of Life	The KOOS is a validated patient oriented outcome measure validated to use in cartilage Research. It assesses five domains, and the Fifth domain (knee related quality of life) will be the primary endpoint in this study. The primary aim is where the primary aim is the difference in KOOS QoL subscore in the AM group compared to the AD group at 24 months follow up.; It is not planned any interim analysis before 24 months follow up.	24 months follow up
Secondary	The Knee Injury and Osteoarthritis Outcome Score (KOOS) Other domains	The other four domains of the KOOS score (pain, symptoms, Activity of daily living, sport and recreational function) will act as secondary endpoints	24 months follow up
Secondary	Tegner Score	A validated knee-score to assess the level of physical Activity.	24 months follow up
Secondary	Lysholm Knee Score	A condition specific knee score that assesses 8 domains: limp, locking, swelling, pain, stair climbing, use of support, instability and squatting.	24 months follow up
Secondary	EQ5D	A generic measure of health status that produces a simple descriptive profile of Health status used in clinical evaluation of Health care.	24 months follow up
Secondary	Visual Analog Scale	A visual analogue scale for pain, where 0 represents no pain and 10 represents the worst pain imaginable.	24 months follow up
Secondary	Range of motion	Clinical evaluation of the joint range of motion	24 months follow up
Secondary	Magnetic Resonance Imaging (MRI) of the cartilage defect	A radiographic evaluation (MRI) of the cartilage injury at 2 years, to evaluate which patients have adequate cartilage quality 2 years after surgery. The MRI will be taken with a cartilage specific protocol.	24 months follow up
Secondary	A Hop test	Clinical evaluation of the knees agility, validated in knee sport medicine Research.	24 months follow up